Interview date - Wednesday 05 August from 10:30am onwards - On site
Hi, my name is Michelle and I'm the Senior Pharmacist Manager for this team. I'm glad that you have looked at the vacancy and are thinking about if it is right for you at this time in your career. Are you a UK registered pharmacist with previous experience of aseptics or manufacturing?
The role is an exciting one offering you the opportunity to focus on the aseptic dispensing of doses for patients in clinical trials or other novel agents. As the Accountable Pharmacist, you will be leading a dedicated team of pharmacists, pharmacy technicians, SMT and healthcare scientists who are passionate about research. Can you show that you combine excellent technical knowledge and skills with those of positive people management?
The other aspects of the role is to support our manufacturing units for radiopharmaceuticals and hyperpolarised gas. Perhaps this isn't something you have done before; we can provide training.
You will work alongside a knowledgeable QA team to ensure that GMP and QAAPS standards continue to be delivered.
At last inspection CTAS was in March 2025 assessed as Low Risk by the SPS QA inspector and you will be in good hands.
We have strong team values and work together to deliver a timely and efficient service through kindness and support for one another.
If this role is of interest, then please get in touch for an informal chat and I look forward to potentially meeting you at interview.
You will be the Accountable Pharmacist for the Clinical Trials Aseptic Services (CTAS) & responsible for the management, leadership and co-ordination of the unlicensed unit providing injectable Investigational Medicinal Products, Advanced Therapy Medicinal Products (ATMPs) and selected high risk injectable medicines to all trust divisions..
You will be responsible for the aseptic preparation of doses for a portfolio of c150 trials and ensuring that GCP requirements are met.
For the MHRA MS Radiopharmacy & Hyperpolarising Gas Units you will line manage the Production Manager(s) and ensure the service is run in compliance with current Good Manufacturing Practice (GMP).
You will work closely with colleagues to ensure that clinical trials for IMPs are set-up in accordance with sponsor requirements and align with UK, trust and pharmacy best practices.
You will act as a role model and source of expert advice for pharmacy and clinical staff for aseptic preparation and ATMPs.
You will act to ensure the safety of the patient and their experience remains at the centre of the service provided, while supporting the well-being of staff across the teams.
You will be supporting the building and commissioning of a new CTAS facility to further enable its extensive research portfolio.
Oxford University Hospitals NHS Foundation Trust is one of the largest NHS teaching trusts in the country. It provides a wide range of general and specialist clinical services and is a base for medical education, training and research. The Trust comprises four hospitals - the John Radcliffe Hospital, Churchill Hospital and Nuffield Orthopaedic Centre in Headington and the Horton General Hospital in Banbury. For more information on OUH please view OUH At a Glance by OUHospitals - Issuu
Our values, standards and behaviours define the quality of clinical care we offer and the professional relationships we make with our patients, colleagues and the wider community.
We call this Delivering Compassionate Excellence and its focus is on our values of compassion, respect, learning, delivery, improvement and excellence.
These values put patients at the heart of what we do and underpin the quality healthcare we would like for ourselves or a member of our family. Watch how we set out to deliver compassionate excellence via the OUH YouTube channel .
See attached job description with person specification for the full details.
Please do take time to read the requirements of the role.
The main responsibilities of this role are to provide the leadership and management to deliver aseptically prepared and manufactured medicines to patients whether as part of clinical trials or specialist care. You will be the Accountable Pharmacist for the Clinical Trials Aseptic Services (CTAS) and responsible for the management and service development of medicines manufactured under the Manufacturing Specials (MS) license.
As the Accountable Pharmacist for CTAS, you will be responsible for the management, leadership and co-ordination of the unlicensed Clinical Trials Aseptic Services unit which provides injectable Investigational Medicinal Products, Advanced Therapy Medicinal Products (ATMPs) and selected high risk injectable medicines to all divisions within the Trust. You will release aseptic doses, train staff, lead and further develop the quality system, worksheet and labelling systems.
The Radiopharmacy & Hyperpolarising Gas Unit hold Manufacturing Specials (MS) Licences and are regulated by the Medicines and Healthcare Products Regulatory Agency (MHRA), you will line manage the Production Manager(s) named on the licences and ensure the service is run in compliance with current Good Manufacturing Practice (GMP). You will release medicines under these license(s).
You will be responsible for the interpretation of complex national and international legislation, applying this to assure the quality of the medicines dispensed and manufactured, whether as part of a clinical trial or standard of care. You will work closely with colleagues to ensure that clinical trials of IMPs are set-up in accordance with sponsor requirements and align with UK, trust and pharmacy best practices.
You will act as a role model and source of expert advice for pharmacy and clinical staff across the Trust in relation to aseptic preparation and production conforming to all appropriate legal requirements and professional guidelines.
You will act to ensure the safety of the patient and their experience remains at the centre of the service provided, while supporting the well-being of staff across their teams.
A key part of the role will be supporting the building and commissioning of a new CTAS facility to further enable its extensive research portfolio.
